2013 Fiscal Year Final Research Report
Vaccination therapy combined with chemotherapy for recurrent pancreatic cancer patients
| Project/Area Number |
23592003
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
AOKI Taku 東京大学, 医学部附属病院, 講師 (30302722)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
長谷川 潔 東京大学, 医学部付属病院, 准教授 (20292906)
國土 典宏 東京大学, 医学部付属病院, 教授 (00205361)
垣見 和広 東京大学, 医学部付属病院, 准教授 (80273358)
松下 博和 東京大学, 医学部付属病院, 助教 (80597782)
中面 哲也 独立行政法人国立がん研究センター, 臨床開発センター, 機能再生室長 (30343354)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 膵癌 / 樹状ワクチン治療 / HSP105 / 用量漸増試験 / 有害事象 / 有効性 / 免疫学的評価 |
|---|
| Research Abstract |
A phase I trial of vaccination therapy using dendrite cells pulsed with HSP105 peptide was conducted. Inclusion criteria were patients with advanced/recurrent cancer with cancer tissue expressing HSP105 and with HLA-A2 or HLA-A24. Dosing-up protocols were applied using 5x106 DC cells/tretament (step 1), 1X107 DC cells/treatment (step 2), and 2X107 DC cells/ treatment (step 3).
In the step 1, CD8 positive T cells specific for HSP105 were not recognized. In the step 2, DTH reaction was found in all the patients. Tumor response was SD in 1, and PD in 2. In the step 3, 4 patients with pancreatic cancer were the candidates, but only one patient received the therapy, as PS deteriorated in the other 3 patients. DTH reaction was also be found, but the tumor response was PD.
|
